Table 1.
Baseline clinical characteristics
| Characteristic | Allo-Allo (n = 55) | Auto-Allo (n = 190) |
|---|---|---|
|
| ||
| Age (years) | ||
| Median (range) | 50 (21–68) | 51 (18–72) |
|
| ||
| Males | 34 (62) | 114 (60) |
|
| ||
| Diagnosis | ||
| AML/MDS/MPD | 38 (69) | 21 (11) |
| ALL | 7 (13) | 2 (1) |
| NHL/HD/CLL | 6 (11) | 108 (57) |
| Multiple Myeloma | 0 | 59 (31) |
| Other | 4 (7) | 0 |
|
| ||
| Reason for second transplant | ||
| Tandem | 0 | 80 (42) |
| Relapse | 36 (65) | 102 (54) |
| Graft failure | 14 (25) | 0 |
| Other reasons including second malignancy | 5 (9) | 8 (4) |
|
| ||
| Disease status (3 missing) | ||
| Relapse | 22 (40) | 134 (71) |
| Remission | 33 (60) | 56 (29) |
|
| ||
| Donor | ||
| Matched related | 10 (18) | 72 (38) |
| Matched unrelated | 31 (56) | 63 (33) |
| Mismatched | 14 (25) | 55 (29) |
|
| ||
| Conditioning | ||
| High intensity | 22 (40) | 52 (27) |
| Reduced intensity/Non-myeloablative | 33 (60) | 138 (73) |
|
| ||
| Stem cell source | ||
| PBSC | 44 (80) | 160 (84) |
| BM | 5 (9) | 28 (15) |
| Cord | 6 (11) | 2 (1) |
|
| ||
| CMV serostatus (7 missing) | ||
| D+/R− | 5 (10) | 22 (12) |
| D+/R+ | 16 (32) | 50 (27) |
| D−/R− | 13 (26) | 57 (30) |
| D−/R+ | 16 (32) | 58 (31) |
|
| ||
| Months between transplants | ||
| Median (range) | 12.8 (1.5–186.2) | 9.6 (1.3–167.8) |
Abbreviations: HCT, Hematopoietic cell transplantation; Allo-allo, 2 allogeneic transplants; Auto-allo, autologous transplant followed by allogeneic transplant; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; ALL, acute lymphoid leukemia; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease; CLL, chronic lymphocytic leukemia; PBSC, peripheral blood stem cell; BM, bone marrow; CMV, Cytomegalovirus; D, donor; R, recipient